Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 14, 2007 Brian Lawler	Sour Results for Nektar Nektar Therapeutics announces its first-quarter financial results and plans for the future. Investors, take note.
The Motley Fool October 19, 2007 Brian Lawler	The Exubera Winner In its third-quarter earnings report, Pfizer announces it is surrendering the rights to market inhalable-insulin treatment Exubera to developer Nektar Therapeutics. Investors, take note.
The Motley Fool December 5, 2008 Brian Orelli	Be Kind to MannKind MannKind has good data on its inhaled insulin drug, but will the FDA approve of it and will diabetics buy it?
The Motley Fool February 29, 2008 Brian Lawler	Nektar Squeezing Along Nektar Therapeutics finishes a topsy-turvy 2007, and gives some good guidance for upcoming year.
The Motley Fool November 3, 2006 Brian Lawler	Nektar Worth Waiting For? Investors might be getting impatient, but the new insulin the company makes is special.
The Motley Fool June 19, 2009 Robert Steyer	MannKind Needs More Leaps Getting FDA approval for its inhaled-insulin product is only one hurdle for this start-up pharmaceutical.
The Motley Fool April 14, 2008 Brian Lawler	MannKind Gets Smacked by Big Brother's Bad News Bad news for a competitor sinks MannKind shares.
The Motley Fool May 6, 2008 Brian Lawler	MannKind Moves Ahead The pharmaceutical awaits pivotal data on its lead drug Technosphere.
The Motley Fool November 13, 2007 Brian Lawler	Nektar's New Old Drug Pfizer returns its non-selling inhalable insulin experiment Exubera to Nektar Therapeutics today, along with $135 million in cash.
The Motley Fool September 9, 2005 Stephen D. Simpson	Diabetics Breathing Easier Investors in Pfizer, Sanofi-Aventis, and Nektar Therapeutics might be breathing a bit easier today. The FDA's expert panel recommended approval for Exubera.
The Motley Fool March 16, 2010 Brian Orelli	How to Lose $114 Million in One Day You've got to be a very trusting investor to buy shares in pharmaceutical company, MannKind.
The Motley Fool December 1, 2004 Brian Gorman	Rational Exuberance Nektar received a positive boost from Pfizer's announcement that it will seek approval for Exubera, an inhaled form of insulin. The drug delivery specialist's stock promptly surged, closing up 23% yesterday.
The Motley Fool May 22, 2006 Stephen D. Simpson	Nektar Full of Potential, Risk Can inhaled insulin sales live up to investors' expectations at Nektar Therapeutics?
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
The Motley Fool January 13, 2006 Stephen D. Simpson	Pfizer Pays Sanofi to Go Away Two large pharmaceutical companies settle a dispute over inhaled insulin, and $1.3 billion changes hands. Investors, take note.
The Motley Fool June 11, 2010 Brian Orelli	Double-Digit Pop Because the Drug Still Works? Developments at Mannkind's shareholder meeting send stock soaring.
The Motley Fool December 31, 2009 Brian Orelli	2010 FDA Decisions to Watch It's a pivotal year for these drugmakers.
The Motley Fool June 26, 2009 Brian Orelli	Rumors and Safety Issues -- One Bad Combination There are rumors floating around that a study will show that use of Sanofi's insulin product, Lantus, has an increased risk of cancer.
The Motley Fool January 16, 2008 Brian Lawler	Another Inhalable Insulin Bites the Dust Novo Nordisk discontinues development of its troubled diabetes treatment and settles its patent infringement lawsuit against Pfizer. Investors, take note.
The Motley Fool June 27, 2005 Stephen D. Simpson	Sniffing Out a Possible Diabetes Blockbuster Inhaled insulin has been a Holy Grail of diabetes care. Will it live up to lofty expectations? Pfizer, Sanofi-Aventis, and Lilly are all interesting in their own right as high-quality pharmaceutical companies, and more aggressive investors should take a look at Nektar and Alkermes, as well.
The Motley Fool July 30, 2010 Brian Orelli	MannKind: Strengths, Weaknesses, Opportunities, Threats It's all about the inhaled insulin.
The Motley Fool May 29, 2007 Brian Lawler	Nektar Squeezes Itself Nektar Therapeutics cuts costs after a slower rollout of its lead compound. Investors, take note.
The Motley Fool September 22, 2010 Brian Orelli	Better Buy: Amylin Pharmaceuticals or MannKind? It's a diabetes-drug showdown.
The Motley Fool June 15, 2010 Brian Orelli	Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug.
The Motley Fool October 22, 2007 Brian Lawler	Not Another Pfizer Pfailure As Pfizer's top execs have said before, losing patent protections on many of its top products around the same time makes for a difficult operating environment. Pfizer's third-quarter results showed just how difficult those losses were.
The Motley Fool March 2, 2005 Bill Mann	How Hated Is Pfizer? The FDA accepts Pfizer's application for what could be a monster drug, and the market yawns.
The Motley Fool March 20, 2008 Brian Lawler	The AIR's Knocked Out of Alkermes Drug developer Alkermes initiates a round of cost-cutting.
The Motley Fool January 22, 2010 Brian Orelli	Pfizer's Great Data Won't Do Much The full data from a clinical trial testing Pfizer's Sutent in pancreatic cancer was truly amazing. Unfortunately, it's not going to do very much for the stock or Pfizer's bottom line.
The Motley Fool September 19, 2006 Brian Lawler	A Long Wait for MannKind The company's inhaled insulin might not reach the market for several years, if it does, but it's a big market. Investors, take note.
Chemistry World June 30, 2014 Phillip Broadwith	Inhaled insulin approved in US Mannkind's Affreza is aimed at reducing the need for patients to inject themselves with insulin so frequently.
The Motley Fool September 17, 2010 Luke Timmerman	Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders?
The Motley Fool June 6, 2011 Brian Orelli	Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market.
Pharmaceutical Executive March 1, 2006 Ron Feemster	Holding Their Breath: Inhaled Insulin Exubera, Pfizer's inhaled-insulin therapy, is carving out a new market for diabetes drugs. Four more companies are looking for their share.
The Motley Fool March 25, 2011 Brian Orelli	Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science.
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
Pharmaceutical Executive May 1, 2009	The Fate of Mannkind Al Mann has sunk almost $1 billion of his own money into a new insulin delivery system. Will FDA be persuaded?
The Motley Fool December 27, 2011 Brian Orelli	2011 No Dreamboat for MannKind An FDA rejection and a long wait is a bad combination.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool May 28, 2010 Brian Orelli	This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope.
The Motley Fool January 8, 2010 Brian Orelli	Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands.
The Motley Fool September 28, 2010 Brian Orelli	Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs.
The Motley Fool August 12, 2011 Evan Niu	One Small Step for Afrezza, One Giant Leap for MannKind Afrezza makes headway toward FDA approval.
The Motley Fool February 25, 2009 Brian Orelli	Pfizer Doesn't Like Reruns The company drops two drugs that had made it as far as phase 3 trials.
The Motley Fool July 20, 2006 Stephen D. Simpson	Pfizer's Big Plans Between the launch of inhaled insulin and spending $34 billion, Pfizer has a lot on its plate. Investors, take note.
The Motley Fool August 7, 2007 Brian Lawler	Nektar Makes a Deal Nektar Therapeutics signs a deal with Bayer AG in an effort to move itself closer to profitability. In return, Bayer gets a co-promotion profit-sharing deal in the U.S., and commercialization rights elsewhere.
The Motley Fool June 29, 2009 Brian Orelli	Lantus Results: Reply Hazy, Try Again Later Drugmaker Sanofi's problems become murkier. Investors are relieved that the data is out -- Sanofi is up about 4.5% at the moment -- but it seems prudent to be cautious here.
The Motley Fool August 6, 2007 Brian Lawler	Unhappy Delays for MannKind Two delays for the inhalable insulin developer cause the stock to drop.
The Motley Fool November 5, 2007 Brian Lawler	Follow the Trend With Novo Nordisk The future is bright for Danish drugmaker Novo Nordisk. The worldwide leader in diabetes treatments turns in another good quarter.
The Motley Fool September 6, 2005 Stephen D. Simpson	FDA's Eye on 2 Potential Blockbusters This week, FDA advisory panels will consider the marketing approval applications of Exubera, the inhaled insulin from Pfizer/Sanofi/Nektar, and Pargluva, the dual PPAR agonist, taken in pill form, from Bristol-Myers and Merck. Investors, take note.
The Motley Fool July 27, 2007 Rich Duprey	Sniffing Out Bentley's New Patent To succeed in insulin therapy, the generic drugmaker must overcome patent expiration. Investors, take note.